Pfizer gets some Celebrex relief

Last week, there was a bit of closure for Merck on Vioxx. This week, a step closer to closure for Pfizer? A federal ruling yesterday may nullify a chunk of Celebrex lawsuits, giving the drug maker a badly needed legal victory. According to the ruling, plaintiffs haven't proven that the pain killer caused heart attacks or strokes when taken at 200 mg daily. That was the most common dosage, Pfizer says.

It's not clear, however, how many of the 3,000 Celebrex plaintiffs used that dose. One plaintiff's lawyer estimates about 900 of them were prescribed 200 mg, but some of them took more than that. Another attorney estimates that about a third of the cases will be eliminated by the ruling.

- read the article from the Wall Street Journal

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.